GlassScriptPhysician profile
Joseph D Baalmann
NPI 1366854416
$6,738.73
in general payments reported to CMS, 2019-2025
32 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $559 · 2021: $1,014 · 2022: $1,128 · 2023: $973 · 2024: $1,203 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,640 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,640.05 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,594.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $882.82 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $648.95 | 2019-2025 | |
| Abbvie INC. | $560.26 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Abbott Laboratories | $428.52 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $336.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $311.94 | 2019-2025 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $300.08 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.25 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $279.59 | 2022-2025 | |
| Glaxosmithkline, LLC. | $169.07 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $164.20 | 2020-2025 | Veozah |
| Merck Sharp & Dohme LLC | $103.40 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Medtronic, INC. | $96.85 | 2025 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $74.50 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $59.09 | 2024-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $49.20 | 2022-2025 | Eliquis |
| Insulet Corporation | $48.83 | 2024-2025 | Omnipod |
| Exact Sciences Corporation | $44.84 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $35.63 | 2019-2021 | |
| Dexcom, INC. | $35.45 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $29.93 | 2020 | |
| Neos Therapeutics, LP | $26.51 | 2022 | |
| Allergan, INC. | $24.70 | 2020 | |
| Seqirus USA INC | $24.69 | 2025 | Fluad, Flucelvax |
| Inspire Medical Systems, INC. | $21.70 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.39 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $18.70 | 2020 | |
| Cranial Technologies, INC | $15.27 | 2025 | Doc Band |
| Edwards Lifesciences Corporation | $15.04 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.10 | 2024 | Voquezna |
| Tris Pharma INC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Baalmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.